Refrakter és relabált Hodgkin-lymphomás betegeink kezelésével szerzett tapasztalataink

Translated title of the contribution: Primary refractory and relapsed Hodgkin-lymphoma patients

Zsófia Miltényi, Zsófia Simon, Edit Páyer, László Váróczy, Lajos Gergely, Árpád Illés

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recovery have been achieved in the majority of Hodgkin-lymphoma patients. Unfortunately some of the patients refracter and about third of the patients relapsed after the first-line treatment. Aim and methods: We investigated the frequency and treatment of refracter or relapsed Hodgkin lymphoma patients between 1996 and 2006. Results: We examined 76 women and 71 men, who had HL in this period. 141 patients (95,9%) had remission after first-line therapy. 6 women were primary refracter, 4 of them had high-dose therapy and autolog stem cell transplantation. They died in spite of the multiple treatment. 31 patients - 13 men and 18 women - had relapse (16 cases were in one year). 14 patients had high-dose therapy and autolog stem cell transplantation, 11 patients had only chemotherapy, 3 had only radiotherapy and 3 patients were treated by combined modality treatment. 6 of the relapsed patients were died, 5 because of the progression of lymphoma and one because of secunder myelodysplasia. Conclusions: Relapsed patients have a good prognosis, but refracter patients have long chance despite autolog or allogen hemopoietic stem cell transplantation. Searching for new therapeutical modalities for these patients is extremely important.

Translated title of the contributionPrimary refractory and relapsed Hodgkin-lymphoma patients
Original languageHungarian
Pages (from-to)172-178
Number of pages7
JournalOrvosi hetilap
Volume151
Issue number5
DOIs
Publication statusPublished - Jan 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Primary refractory and relapsed Hodgkin-lymphoma patients'. Together they form a unique fingerprint.

  • Cite this